Journal editorial - The emerging story of Myval transcatheter heart valve: lessons from the LANDMARK trial
ESC Cardio Talk
00:00
Overall LANDMARK sub-study takeaway
Paolo concludes Myval shows balanced short-term hemodynamics, less PPM than Sapien, and competitive performance overall.
Play episode from 06:26
Transcript
